#Canada #Vancouver #Hydreight Technologies #Pawsible Ventures #Victory Square

Victory Square Technologies Financial Report Q1 2026

Victory Square Technologies Inc. has recently unveiled its financial results for the first quarter of 2026, showcasing notable growth and the ongoing evolution of its portfolio. The Vancouver-based company, known for its focus on healthcare infrastructure, digital health, and artificial intelligence, reported impressive increases in both revenue and net income compared to the same period last year.

Financial Highlights

In Q1 2026, Victory Square achieved a revenue of $24.9 million, a significant rise from $4.5 million reported in Q1 2025. The company's gross profit also saw an uplift, reaching $5.1 million, compared to $1.5 million in the previous year. Their net income totaled approximately $3.9 million, while cash and marketable securities climbed to around $31 million as of March 31, 2026. These financial metrics illustrate a strengthened liquidity position, allowing the company increased financial flexibility.

CEO Shafin Diamond Tejani commented on these figures, emphasizing their commitment to supporting businesses within the healthcare and technology sectors.

Portfolio Companies Update

Victory Square’s robust revenue growth is largely attributed to its flagship operating subsidiary, Hydreight Technologies. This company has developed a comprehensive healthcare platform that provides continuous support across telehealth, physician coverage, and pharmacy relational frameworks.

Hydreight Technologies Highlights

Hydreight continues to solidify its position as a leader in its field. Key updates include:

• - Achieving significant revenue growth and profitability.
• - Expanding its VSDHOne platform to over 12,000 licenses.
• - Successfully securing a financing round of $15 million.
• - Initiating a Normal Course Issuer Bid (NCIB) to enhance shareholder value.

These developments indicate Hydreight’s commitment to providing exceptional support to healthcare entrepreneurs, clinics, and brands through its technological capabilities.

Insu Therapeutics Update

Insu Therapeutics, a clinical-stage biotechnology firm within the Victory Square portfolio, is working on a revolutionary buccal delivery system for peptide-based therapies. This system is designed to bypass traditional gastrointestinal absorption which is often a limitation in drug delivery.

During the first quarter, Insu completed Phase I preclinical studies for its innovative buccal semaglutide program and received ethics approval for Phase II studies at the University of British Columbia.

New Initiatives by Pawsible Ventures

Pawsible Ventures is another exciting venture launched by Victory Square. Over the past year, it has evaluated hundreds of companies and launched initiatives targeting veterinary care, artificial intelligence in pet health, and related fields. The global pet care market is booming, with current estimates exceeding $270 billion annually and predicted to approach $500 billion in the next decade due to increasing pet ownership and spending.

Pawsible Ventures launched a dedicated pet healthcare platform, a $10 million investment fund, and a venture studio targeted at fostering innovation in veterinary diagnostics and health.

Looking Forward

Victory Square Technologies continues its journey with robust plans for the future which include:

• - Ongoing support for Hydreight's growth and expansion initiatives.
• - Advancing Insu Therapeutics' research programs.
• - Continuing the roll-out of Pawsible Ventures' initiatives in pet health.

The management is committed to exploring monetization opportunities and ensuring disciplined capital allocation across its portfolio.

Upcoming Webinar

Investors can expect a detailed discussion of Victory Square's financial results and upcoming strategies during a live webinar on June 9, 2026. The management encourages shareholders to submit questions in advance.

Victory Square Technologies is poised for further success, thanks to its innovative portfolio and strategic growth direction. By focusing on healthcare infrastructure and technology, the company continues to establish a strong foothold in various emerging sectors.